Current study (N=106) | Bot et al19 (N=33) | P value | |
Inclusion period | 2016–2019 | 2007–2011 | |
DBS electrodes/hemibodies, N | 212 | 65 | |
Non-responding, % (N) | 17% (37) | 26% (17) | 0.107 |
Responding, % (N) | 51% (108) | 46% (30) | 0.481 |
Optimally responding, % (N) | 32% (67) | 28% (18) | 0.543 |
Hemibody MDS-UPDRS ME improvement, mean±SEM* | 53%±2.0% | 48%±5.0% | 0.416 |
Q1, mean±SEM | 13%±2.7% | −8%±9.9% | 0.044† |
Q2, mean±SEM | 47%±0.8% | 48%±2.4% | 0.886 |
Q3, mean±SEM | 65%±0.8% | 67%±1.0% | 0.179 |
Q4, mean±SEM | 85%±1.0% | 86%±2.1% | 0.781 |
*Bootstrap for independent t-test based on 1000 samples.
† Statistically significant.
DBS, deep brain stimulation; MDS-UPDRS ME, Movement Disorder Society–Unified Parkinson’s Disease Rating Scale Motor Examination.